What indicators do you use to determine whether a patient is having a favorable or unfavorable response to nintedanib?

Unfortunately, there probably isn't a way to do this. It might be helpful to step back and see what nintedanib buys you: as compared to placebo, the nintedanib group suffered less FVC decline by ~110mL/year. Real-world data suggest there's probably a mortality benefit if you have your patients on it...

At the present time, the best we can achieve is slowing and stabilization of fibrosis. This is important because there is a direct correlation with decrement in lung function and the extent of disease as seen on HRCT with patient morbidity and mortality. Patient symptoms, FVC, DlCo, and HRCT are all...

I look for evidence of stabilization of decline in pulmonary function testing coupled with tolerability from a side effect standpoint. I always have a shared medical decision discussion with my patients. My goal is to stabilize their lung function (which hopefully translates into longer life lived, ...